Quick Facts

• 350 women recruited into a prospective study
• Approximately ⅔ of women reported using medications for UF-associated pain
• Participants experienced, on average, a 9-year gap from symptom onset to diagnosis

‍

Challenge

• Uterine fibroids (UF) affect up to 70% of women by age 50, with 20-50% experiencing clinical symptoms impacting daily life; the most common symptoms include pain and heavy menstrual bleeding (HMB)
• Limited evidence exists on the patient-perceived disease burden of UF from prospective, observational studies
• Myovant had two main objectives:‍

• Describe the demographic and clinical characteristics of women living with HMB and moderate-to-severe pain associated with UF in clinical practice
• Assess the real-world utilization of therapies to treat these symptoms of UF

‍

Approach

• Evidation leveraged its digital health measurement and engagement platform to recruit 350 women living with UF, moderate-to-severe pain, and HMB into a 4-month prospective study to assess the burden of pain and its related treatments
• In addition to clinical and demographic characteristics, patients completed UF-specific ePROS using the UFS-QOL-SS scale, 11-point NRS on UF-associated pain, and daily surveys on pain medication use

‍

Results

• Participants reported a mean UF-symptom severity of 51.2 (± 19.2) and a mean worst UF-associated pain score of 7.17 (± 1.54)
• These findings provide evidence of the significant burden that UF imposes on women – while symptom onset occurred early in life, women experienced, on average, a 9-year gap from symptom onset to diagnosis
• Women mainly managed their UF-associated pain with over-the-counter medications, while not receiving treatments for HMB; hence, there are significant unmet diagnostic as well as treatment needs in UF